New blood clot pill could replace daily shots for joint replacement patients
NCT ID NCT07124819
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compared an experimental oral anticoagulant called Dimolegin to the standard injectable drug Clexane for preventing venous thromboembolism (VTE) in 215 adults undergoing hip or knee replacement surgery. The goal was to see if the pill is as effective and safe as the injection in reducing blood clots, clot-related deaths, and bleeding events. If successful, Dimolegin could offer a more convenient, needle-free option for post-surgery clot prevention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dimolegin (oral anticoagulant)
What this could lead to
If it works, this could offer a convenient pill alternative to daily injections for preventing dangerous blood clots after joint replacement surgery.
What could go wrong
This is a completed phase 3 trial with 215 participants, but results are not yet published. The new drug may not be as effective or safe as the standard treatment, and bleeding risks are a concern.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bryansk City Hospital No. 1
Bryansk, Russia
-
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Moscow, Russia
-
National Research Ogarev Mordovia State University
Saransk, Russia
-
Privolzhsky Research Medical University
Nizhny Novgorod, Russia
-
Rostov State Medical University
Rostov-on-Don, Russia
-
Ryazan State Medical University named after academician I.P. Pavlov
Ryazan, Russia
-
Samara Regional Clinical Hospital named after V.D. Seredavin
Samara, Russia
-
Saratov State Medical University named after V. I. Razumovsky
Saratov, Russia